Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG
Status:
Suspended
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
Coronary Artery Bypass Graft (CABG) is a surgical procedure known to be associated with
cognitive impairment. Mechanisms of cognitive impairment are complex but may include
insufficient oxygenation and inflammation due to exposure to the bypass circuit. Currently
there are no approved therapeutics for the prevention or treatment of cognitive impairment in
these patients.
A small peptide, Angiotensin-(1-7) [Ang-(1-7)], is known to decrease inflammation in the
brain in animal models. Early studies in humans have shown it to be safe. This peptide is
naturally produced by the body and has anti-inflammatory and vasodilatory effects.
Investigators believe that Ang-(1-7) may be able to help lower the risk of cognitive
dysfunction in patients undergoing CABG.
The goal of this project is to explore effects of the experimental peptide Angiotensin-(1-7)
(Ang-(1-7) in patients undergoing an elective CABG surgery to determine its safety and
efficacy to prevent cognitive dysfunction in patients undergoing CABG.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) Suburban Hospital